Table 2.
Antiproliferative screening of novel compounds 2–6 towards human cancer cell lines (U2OS, HepG2, MCF‐7) and human embryonic kidney cell line (Hek293) in vitro.
| Compd | Structure | IC50 [a] [μm] | |||
|---|---|---|---|---|---|
| U2OS | HepG2 | MCF‐7 | Hek293 | ||
| 2 a |
|
6.7±3.1 | >50 | >50 | >50 |
| 2 b |
|
14.9±2.2 | >50 | >50 | 17.0±1.7 |
| 2 c |
|
>50 | >50 | >50 | >50 |
| 2 d |
|
24.3±1.5 | >50 | 5.3±3.2 | >50 |
| 2 e |
|
>50 | >50 | 7.1±3.0 | >50 |
| 3 a |
|
>50 | >50 | >50 | >50 |
| 3 b |
|
>50 | >50 | >50 | >50 |
| 3 c |
|
33.8±2.9 | >50 | >50 | >50 |
| 3 d |
|
>50 | >50 | >50 | >50 |
| 3 e |
|
>50 | >50 | 15.2±0.5 | >50 |
| 4 a |
|
>50 | >50 | 12.0±1.4 | >50 |
| 4 b |
|
>50 | >50 | >50 | >50 |
| 4 c |
|
>50 | >50 | 16.6±0.8 | >50 |
| 4 d |
|
32.8±3.0 | 9.9±1.1 | 13.9±1.5 | >50 |
| 4 e |
|
7.1±1.2 | >50 | 11.5±0.1 | 13.2±2.6 |
| 5 a |
|
16.9±2.2 | 18.0±3.3 | 5.4±0.1 | 25.5±0.8 |
| 5 b |
|
3.3±0.05 | 20.0±0.2 | 1.6±0.8 | 8.5±0.5 |
| 5 c |
|
11.6±2.0 | 28.4±2.1 | 5.0±0.4 | 13.7±3.4 |
| 5 d |
|
11.6±2.1 | 21.7±0.2 | 4.7±0.1 | 6.1±1.9 |
| 6 a |
|
6.6±1.2 | >50 | 5.9±0.6 | 8.6±2.0 |
| 6 b |
|
>50 | >50 | 10.0±2.8 | >50 |
| 6 c |
|
>50 | >50 | 7.1±0.4 | >50 |
| 6 d |
|
>50 | >50 | 9.8±0.4 | >50 |
| 6 e |
|
>50 | >50 | >50 | >50 |
| PQ[b] | 12.0±0.7 | 37.7±5.8 | 13.8±1.4 | 8.1±1.3 | |
| SAHA[c] | 5.7±0.8 | 4.0±0.1 | 2.8±0.7 | 7.4±0.9 | |
| Cis[d] | 2.5±0.7 | – | 3.2±1.0 | 2.0±0.6 | |
[a] The concentration required to decrease viability by 50 %. [b] Primaquine. [c] Suberoylanilide hydroxamic acid. [d] Cisplatin.